TuHURA Biosciences

HURA · Nasdaq · United States

Share price · HURA

$1.37-0.79 (-36.57%) 3M

close as of 2026-11-18 · 24h delayed · vol 194K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HURA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Oct 2026+8.5%
  2. 21 Oct 2026+18.5%
  3. 21 Aug 2026-9.9%
  4. 26 Jun 2026-16.6%

    Nothing announced by HURA that day or the session before.

  5. 18 Jun 2026+15.8%
  6. 10 Feb 2026+60.5%

    Nothing announced by HURA that day or the session before.

  7. 9 Feb 2026+28.8%

    Nothing announced by HURA that day or the session before.

  8. 6 Feb 2026+43.0%

    Nothing announced by HURA that day or the session before.

  9. 24 Dec 2025+15.2%

    Nothing announced by HURA that day or the session before.

  10. 10 Dec 2025-12.0%

Share of unusual movement by asset

For each asset, the share of HURA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—70%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Innate immune activation (intralesional plasmid DNA)Gene therapy / editing
Merkel Cell Carcinoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
IFx-2.0Phase 2/3Advanced Or Metastatic Merkel Cell Carcinoma
Est. primary completion 2027-03-31 · NCT06947928 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$3.7M$1.9M$6.4M-$5.0M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.6M$1.0M$9.2M-$8.6M operating cash flowreport ↗
2026-Q1$0$5.2M$6.3M$7.5M-$4.4M operating cash flowreport ↗
2025-Q3—$5.0M$2.7M$7.1M-$11M operating cash flowreport ↗
2025-Q2—$4.9M$8.5M$9.5M-$6.3M operating cash flowreport ↗
2025-Q1$0$4.6M$6.2M$6.7M-$4.7M operating cash flowreport ↗
2024-Q3—$0.3M$3.0M$2.2M-$1.9M operating cash flowreport ↗
2024-Q2—$2.8M$4.9M$5.3M-$1.4M operating cash flowreport ↗
2024-Q1$0$0.6M$6.3M$2.0M-$3.8M operating cash flowreport ↗
2023-Q4—$0.1M$0.7M$1.0M-$2.1M operating cash flowreport ↗
2023-Q3—$1.9M$0.2M$3.0M-$1.3M operating cash flowreport ↗
2023-Q1—$2.0M$3.0M$3.3M-$1.8M operating cash flowreport ↗
2022-Q4—$2.1M$4.9M$3.5M-$2.2M operating cash flowreport ↗
2022-Q3—$3.2M$7.1M$4.6M-$6.4M operating cash flowreport ↗
2022-Q1—$3.5M$8.8M$5.4M-$5.2M operating cash flowreport ↗
2021-Q4—$3.9M$14M$5.9M-$5.1M operating cash flowreport ↗
2021-Q3—$3.8M$19M$6.0M-$5.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$21M$3.6M$7.5M-$28M operating cash flowreport ↗

TuHURA Biosciences reported revenue of $0M for FY2025, with R&D spend of $20.53M. Cash and equivalents totaled $3.62M, while the company posted a net loss of $30.05M, corresponding to a quarterly net burn of $30.05M.

TuHURA is a Phase 3 clinical-stage immuno-oncology company focused on overcoming resistance to cancer immunotherapies. During the period, it initiated a Phase 3 registration trial of IFx-2.0 as an adjunctive therapy to pembrolizumab in first-line advanced or metastatic Merkel cell carcinoma, completed its acquisition of Kineta in June 2025, and gained rights to the VISTA-inhibiting antibody TBS-2025, with a planned Phase 1b/2 trial in relapsed/refractory mutated NPM1 AML. The company is also advancing DOR-targeting bi-specific ADC candidates in preclinical development.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$2.7M$4.9M$2.1M-$7.2M operating cash flowreport ↗
2023-FY$0$9.3M$1.5M$3.7M-$12M operating cash flowreport ↗
2022-FY—$15M$12M$5.7M-$20M operating cash flowreport ↗
2021-FY—$12M$11M$9.6M-$19M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Bianco James A. · director, Chief Executive OfficerGift75,000——Form 4
2026-05-28Bianco James A. · director, Chief Executive OfficerGift150,000——Form 4
2026-02-12Hoffman Robert E. · directorAward / grant (derivative)156,240——Form 4
2026-02-12List Alan · directorAward / grant (derivative)156,240——Form 4
2026-02-12MANUSO JAMES S J · directorAward / grant (derivative)156,240——Form 4
2026-02-12Ng George K · directorAward / grant (derivative)156,240——Form 4
2026-02-12Tendler Craig · directorAward / grant (derivative)156,240——Form 4
2026-01-06Bianco James A. · director, Chief Executive OfficerAward / grant (derivative)610,332——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 9.5M shares ($16.8M, 14.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.2,450,256$4.4M
2VANGUARD CAPITAL MANAGEMENT LLC2,074,228$3.7M
3GEODE CAPITAL MANAGEMENT, LLC986,922$1.8M
4AQR CAPITAL MANAGEMENT LLC607,168$1.1M
5STATE STREET CORP512,913$918K
6NORTHERN TRUST CORP298,187$534K
7VANGUARD FIDUCIARY TRUST CO287,133$514K
8VANGUARD PORTFOLIO MANAGEMENT LLC253,641$454K
9Bank of New York Mellon Corp211,568$379K
10Apollon Wealth Management, LLC158,010$283K
11Cetera Investment Advisers140,244$251K
12Suncoast Equity Management104,409$187K
13CHARLES SCHWAB INVESTMENT MANAGEMENT INC98,937$177K
14WealthShield Partners, LLC91,530$164K
15IEQ CAPITAL, LLC81,316$146K